This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baumgartner, I. Articles by Isner, J. M. Search for Related Content PubMed PubMed Citation Articles by Baumgartner, I. Articles by Isner, J. M.

(Circulation. 1998;97:1114-1123.)
© 1998 American Heart Association, Inc.

Clinical Investigation and Reports

Constitutive Expression of phVEGF₁₆₅ After Intramuscular Gene Transfer Promotes Collateral Vessel Development in Patients With Critical Limb Ischemia

Iris Baumgartner, MD; Ann Pieczek, RN; Orit Manor, PhD; Richard Blair, MD; Marianne Kearney, BS; Kenneth Walsh, PhD; ; Jeffrey M. Isner, MD

From the Departments of Medicine (Cardiology) (I.B., A.P., J.M.I.), Radiology (R.B.), and Biomedical Research (I.B., O.M., M.K., K.W., J.M.I.), St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Mass.

Correspondence to Jeffrey M. Isner, MD, St Elizabeth's Medical Center of Boston, 736 Cambridge St, Boston, MA 02135. E-mail jisner{at}opal.tufts.edu

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—Preclinical studies have indicated that angiogenic growth factors can stimulate the development of collateral arteries, a concept called "therapeutic angiogenesis." The objectives of this phase 1 clinical trial were (1) to document the safety and feasibility of intramuscular gene transfer by use of naked plasmid DNA encoding an endothelial cell mitogen and (2) to analyze potential therapeutic benefits in patients with critical limb ischemia.

Methods and Results—Gene transfer was performed in 10 limbs of 9 patients with nonhealing ischemic ulcers (n=7/10) and/or rest pain (n=10/10) due to peripheral arterial disease. A total dose of 4000 µg of naked plasmid DNA encoding the 165-amino-acid isoform of human vascular endothelial growth factor (phVEGF₁₆₅) was injected directly into the muscles of the ischemic limb. Gene expression was documented by a transient increase in serum levels of VEGF monitored by ELISA. The ankle-brachial index improved significantly (0.33±0.05 to 0.48±0.03, P=.02); newly visible collateral blood vessels were directly documented by contrast angiography in 7 limbs; and magnetic resonance angiography showed qualitative evidence of improved distal flow in 8 limbs. Ischemic ulcers healed or markedly improved in 4 of 7 limbs, including successful limb salvage in 3 patients recommended for below-knee amputation. Tissue specimens obtained from an amputee 10 weeks after gene therapy showed foci of proliferating endothelial cells by immunohistochemistry. PCR and Southern blot analyses indicated persistence of small amounts of plasmid DNA. Complications were limited to transient lower-extremity edema in 6 patients, consistent with VEGF enhancement of vascular permeability.

Conclusions—These findings may be cautiously interpreted to indicate that intramuscular injection of naked plasmid DNA achieves constitutive overexpression of VEGF sufficient to induce therapeutic angiogenesis in selected patients with critical limb ischemia.

Key Words: angiogenesis • genes • ischemia • growth substances

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Critical limb ischemia is estimated to develop in 500 to 1000 individuals per million per year.¹ In a large proportion of these patients, the anatomic extent and the distribution of arterial occlusive disease make the patients unsuitable for operative or percutaneous revascularization, and the disease thus frequently follows an inexorable downhill course.^{2 3} Psychological testing of such patients has disclosed quality-of-life indices similar to those of patients with cancer in the terminal phase of their illness.⁴ As concluded in the Consensus Document of the European Working Group on Critical Limb Ischemia,¹ no pharmacological treatment has been shown to favorably affect the natural history of critical limb ischemia.⁵ Indeed, amputation, despite its associated morbidity, mortality, and functional implications,^{1 6 7 8} is often recommended as a solution to the disabling symptoms, in particular excruciating ischemic rest pain, of critical limb ischemia.^{9 10 11 12} A second major amputation will be required in nearly 10% of such patients. Despite the use of prosthetics and rehabilitation, reestablishment of full mobility is inconsistently achieved, particularly in the elderly. Consequently, the need for alternative treatment strategies in patients with critical limb ischemia is compelling.

Preclinical studies have indicated that angiogenic growth factors can stimulate the development of collateral arteries in animal models of peripheral^{13 14} and myocardial^{15 16 17} ischemia, a concept called therapeutic angiogenesis. Several of these studies have used VEGF, also known as vascular permeability factor, a secreted endothelial-cell mitogen with high-affinity binding sites limited to endothelial cells.^{18 19 20 21 22} Endothelial cell specificity has been considered to represent an important advantage of VEGF for therapeutic angiogenesis, because endothelial cells represent the critical cellular element responsible for new vessel formation.^{23 24 25}

We recently demonstrated angiographic and histological evidence of angiogenesis after intra-arterial gene transfer of naked plasmid DNA encoding human VEGF in a patient with critical limb ischemia.²⁶ In this report, we present the results of intramuscular phVEGF₁₆₅ gene transfer performed in an initial phase 1 clinical trial comprising 9 patients with 10 critically ischemic limbs.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Patients
Patients qualified for intramuscular gene therapy if they (1) had chronic critical limb ischemia¹ including rest pain and/or nonhealing ischemic ulcers present for a minimum of 4 weeks without evidence of improvement in response to conventional therapies and (2) were not optimal candidates for surgical or percutaneous revascularization.²⁷ Requisite hemodynamic deficit included a resting ABI <0.6 and/or TBI <0.3 in the affected limb on 2 consecutive examinations performed at least 1 week apart. Criteria used to describe a change in limb status were adapted from standards recommended by the Society for Vascular Surgery/North American Chapter and International Society for Cardiovascular Surgery.^{3 28} Patients were allowed to continue on aspirin and coumarin, provided that these therapies had been used for a minimum of 6 months before gene transfer. Vasoactive medications were discontinued unless prescribed for cardiac disease or systemic hypertension. All patients gave written informed consent for their participation. The study was designed as a phase 1, nonrandomized study to document the safety of intramuscular phVEGF₁₆₅ gene transfer and to monitor patients as well for evidence of bioactivity. This study design was unanimously approved by the Recombinant DNA Advisory Committee of the National Institutes of Health, by the Human Institutional Review Board and Institutional Biosafety Committee of St Elizabeth's Medical Center, and by the US Food and Drug Administration.

Plasmid DNA (phVEGF₁₆₅)
All patients received a eukaryotic expression vector encoding the VEGF₁₆₅ gene²⁹ transcriptionally regulated by the cytomegalovirus promoter/enhancer.²⁶ Preparation and purification of the plasmid from cultures of phVEGF₁₆₅-transformed Escherichia coli were performed in the Human Gene Therapy Laboratory at St Elizabeth's Medical Center by the column method (Qiagen Mega Kit, Qiagen, Inc). The purified plasmid was stored in vials and pooled for quality control analyses.

Intramuscular phVEGF₁₆₅ Transfer
Aliquots of 500 µg of VEGF₁₆₅ pDNA were diluted in sterile saline, and 4 aliquots (total, 2000 µg) were administered into calf and/or distal thigh muscles of the patients by direct intramuscular injection into the ischemic limb. The injection sites were arbitrarily selected according to available muscle mass and included sites above as well as below the knee. The volume of each of the 4 injectates per limb was progressively increased during the course of the study from 0.75 mL (3 treatments) to 3 mL (6 treatments) to 5 mL (11 treatments). Four weeks after the first 2000-µg injection, a second 2000-µg injection was administered, increasing the total amount of pDNA to 4000 µg per patient. One patient was treated for bilateral critical limb ischemia with a total amount of 8000 µg pDNA (4000 µg per limb).

Serum VEGF Levels
ELISAs were performed at baseline and weekly up to 12 weeks after the initial treatment of 7 limbs to detect evidence of gene expression at the protein level. Samples were immediately centrifuged for 20 minutes at 3600 rpm at 4°C, and the serum was stored at -20°C until analysis. Serum VEGF was determined with an immunoassay according to the manufacturer's instructions (R&D Systems). Results were compared with a standard curve of human VEGF with a lower detection limit of 5 pg/mL. Samples were checked by serial dilution and were performed at least in duplicate.

Hemodynamic and Angiographic Assessment
Patients were followed up on a weekly basis within the first 8 weeks after gene therapy and at monthly intervals thereafter. Ischemic ulcers were documented by color photography. Resting ABI and TBI were calculated by the quotient of absolute ankle or toe pressure to brachial pressure.³⁰ Intra-arterial digital subtraction angiography and MRA were performed within 1 week before and 4 weeks after each treatment and 3 months after the latter of 2 intramuscular injections. Digital subtraction angiography was performed as a selective single-leg runoff study using undiluted nonionic contrast media (Isovue-370, Squibb Diagnostics). A minimum of 2 images (early and late frames) at the thigh, knee, calf, and ankle/foot levels were recorded by digital acquisition and hard copies in a 35x45-cm format. The diameter of newly visible collateral vessels was assessed by comparison with a 0.09-in-diameter reference wire taped to the skin. MRA was performed with a 1.0-T superconducting system (Impact, Siemens) by means of a transmit-receive extremity coil, a body coil, or both and commercially available pulse sequences. A multisection two-dimensional time-of-flight gradient echo sequence without intravenous contrast medium was used.³¹ All axial images were reconstructed by use of the maximum-pixel-intensity algorithm at intervals of 60°.

Immunohistochemistry
Double immunohistochemical staining for proliferating endothelial cells was performed as previously described.³² Bound antibody was then detected with an alkaline phosphatase kit (Biogenex Laboratories). Complexes were visualized with fast red substrate (Biogenex Laboratories). A counterstain of 10% Gill hematoxylin was applied before coverslips were applied.

DNA Analysis
Skin specimens at the site of gene injection and muscle specimens near or remote from the site of gene injection were retrieved from 2 amputees 8 and 10 weeks after intramuscular phVEGF₁₆₅ transfer, respectively (patients 4 and 10, Table). Tissue was processed with a genomic DNA isolation kit (A.S.A.P., Boehringer Mannheim). For PCR analysis, primer sets unique to the promoter and VEGF coding region of phVEGF₁₆₅ were selected. For Southern analysis, EcoR1-digested total cellular DNA (30 µg) and purified phVEGF₁₆₅ DNA (0.5 µg) were subjected to 0.8% agarose electrophoresis. The predicted sizes of EcoR1-digested plasmid fragments were 998 and 4703 bp. DNA blotted to a nylon membrane (Amersham, Life Science) was hybridized with two ³²P-labeled phVEGF₁₆₅-specific probes (ncoI-digested 679-bp phVEGF₁₆₅ fragment, position 389 to 1068; avaI-digested 787-bp phVEGF₁₆₅ fragment, position 991 to 1778), washed, and exposed to Hyperfilm MP (Amersham, Life Science).

View this table: [in this window] [in a new window]   Table 1. Clinical, Hemodynamic, Angiographic, Laboratory, and Molecular Findings Before and After Intramuscular phVEGF165 Gene Transfer

Statistical Analysis
Data are reported as mean±SEM. Comparisons between paired variables were performed with the nonparametric Friedman test and Wilcoxon rank sum test. All statistical tests were two-tailed, with a significance level of P<.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Demographic and clinical data for the 5 women and 4 men (mean age, 59±19 years) treated with phVEGF₁₆₅ are shown in the Table. Average length of follow-up at the time of this report was 6±3 months (range, 2 to 11 months). Local intramuscular gene transfer induced no or mild local discomfort up to 72 hours after the injection. Serial creatine phosphokinase measurements remained in the normal range, there were no signs of systemic or local inflammatory reactions, and no patient developed antibodies to VEGF. To date, neither loss of visual acuity nor change in funduscopic examination due to diabetic retinopathy³³ has been observed in any patient treated with phVEGF₁₆₅ gene transfer. Likewise, no development of a latent neoplasm³⁴ has been observed. The only complication seen was transient lower-extremity edema, consistent with VEGF enhancement of vascular permeability.³⁵

Transgene Expression
Blood levels of VEGF transiently peaked 1 to 3 weeks after gene transfer in 7 patients in whom weekly blood samples were obtained (Fig 1). (In 2 patients, baseline and/or more than two follow-up blood samples were not obtained.) Indirect clinical evidence of VEGF overexpression was evident from the development of peripheral edema (+1 to +4 by gross inspection) in the 6 patients with ischemic ulcers. In 4 of these patients, edema was limited to the treated limb, whereas in 2 patients, the contralateral limb was affected as well, albeit less severely. The onset of edema corresponded temporally to the rise in serum VEGF levels.

View larger version (15K): [in this window] [in a new window]   Figure 1. Serial levels of VEGF determined by ELISA disclosed a transient elevation 1 to 2 weeks after intramuscular (phVEGF165) gene transfer. Baseline and/or weekly follow-up venous blood samples, which were incomplete in 3 of 10 treated limbs (patients 2, 8, and 10 in the Table), are not shown.

Noninvasive Arterial Testing
Absolute systolic ankle or toe pressure increased in 8 limbs after gene transfer and was unchanged in 1 limb at the time of the most recent follow-up (53±4.8 at baseline, 66±4.6 most recent follow-up, P=.008). ABI and/or TBI increased from 0.33±0.05 (range, 0 to 0.58; n=10) at baseline to 0.43±0.04 (0.22 to 0.57, P=.028; n=10) at 4 weeks, to 0.45±0.04 (0.27 to 0.59, P=.016; n=10) at 8 weeks, and to 0.48±0.03 (0.27 to 0.67, P=.017; n=8) at 12 weeks (Fig 2). Improvement in the pressure index was sustained, but the increases in values obtained after the second (4-week) injection were not significantly different from measurements made 4 weeks after the initial injection. Exercise performance improved in all 5 patients with rest pain or ischemic ulcers who were able to perform graded treadmill exercise.³⁶ All patients experienced a significant increase in pain-free walking time (2.5±1.1 minutes before gene therapy versus 3.8±1.5 minutes at an average of 13 weeks after gene therapy, P=.043). A statistically significant increase in absolute, claudication-limited walking time (4.2±2.1 minutes before versus 6.7±2.9 minutes after gene therapy, P=.018) was documented as well. Two patients reached the target end point of 10 minutes of exercise.

View larger version (21K): [in this window] [in a new window]   Figure 2. Gain in ABI and/or TBI in 10 limbs 4 and 8 weeks after intramuscular phVEGF165 gene transfer. *Mean values, P=.02.

Angiography
Digital subtraction angiography showed newly visible collateral vessels at the knee, calf, and ankle levels in 7 of 10 treated ischemic limbs. The luminal diameter of the newly visible vessels ranged from 200 to >800 µm, although most were closer to 200 µm; the latter frequently appeared as a "blush" of innumerable collaterals (Fig 3A and 3B). Follow-up angiograms disclosed no evidence of collateral artery regression in any patients. Serial magnetic resonance angiograms of the ischemic limb disclosed qualitative evidence of improved distal blood flow in 8 limbs, including enhancement of signal intensity in previously identified vessels, and an increase in the number of newly visible collaterals (Fig 3C and 3D).

View larger version (102K): [in this window] [in a new window]   Figure 3. A and B, Newly visible collateral vessels at calf level 8 weeks after phVEGF165 gene transfer. Luminal diameter of newly visible vessels ranged from 200 to >800 µm (arrow); most were closer to 200 µm, and these frequently appeared as a blush of innumerable collaterals. C and D, MRA before and 8 weeks after gene therapy. After gene therapy, signal enhancement is clearly evident, consistent with improved flow in ischemic limb.

Change in Limb Status and Ischemic Rest Pain
Therapeutic benefit was demonstrated by regression of rest pain and/or improved tissue integrity in the ischemic limb. Limb salvage, for example, was achieved in a 33-year-old woman (patient 1, Table), who had undergone 7 unsuccessful surgical reconstructions at another hospital. She presented with a necrotic great toe and a 9x3-cm ischemic ulcer at the site of vein harvest in her distal left limb (Fig 4). The ulcer had failed to respond to 6 months of conservative measures, during the last 3 of which she had been treated with methadone, oxycodone/acetaminophen, amitriptyline hydrochloride, and a fentanyl patch. She had been advised by her vascular surgeons to undergo below-knee amputation. Within 8 weeks after gene transfer, her ABI had increased by 0.24, and the ulcer dimensions had diminished sufficiently to permit placement of a split-thickness skin graft. The graft healed successfully and remained healed at 9-month follow-up (Fig 4). A second patient, a 39-year-old woman (patients 4 and 8, Table), presented with a 3-month history of gangrene of the distal half of her right foot. Although the ABI in her right limb improved by 0.27 after gene transfer, the forefoot gangrene was not reversed, and she underwent right below-knee amputation. While she was being treated for the right limb, however, she developed gangrene in the left limb (Fig 5). After gene transfer to the left limb, the ABI in her left lower extremity increased by 0.22 in association with angiographically demonstrable, newly visible collateral vessels. Although she required amputation of the left great toe, the operative site healed promptly, and her remaining 4 toes and heel recovered completely, including restoration of normal nail growth (Fig 5). In 2 other patients, complete (patient 2, Table) or partial (patient 6, Table) healing of ischemic ulcers present for 12 and 2 months, respectively, avoided major limb amputation. In the 3 patients (patients 5, 7, and 9, Table) who presented with rest pain (of 6, 5, and 3 months' duration, respectively) unassociated with loss of tissue integrity, rest pain resolved completely in all 3 patients after gene transfer and has remained so at the most recent follow-up.

View larger version (43K): [in this window] [in a new window]   Figure 4. Limb salvage after gene therapy in a 33-year-old woman (patient 1, Table). Left top, Nonhealing wound on medial aspect of calf and ischemic necrosis involving great toe. Left middle, Ingrowth of granulation tissue in calf wound, healing of great toe. Left bottom, Three months after gene transfer, healing of split-thickness skin graft at wound site and full resolution of great toe necrosis. Before gene therapy, patient was wheelchair-bound on multiple analgesics, including methadone, amitriptyline hydrochloride, clonidine, oxycodone/acetaminophen, and a fentanyl patch. Three months after gene transfer, she was freely ambulatory and had been successfully weaned from all analgesics. Right, Evidence of phVEGF165 bioavailability documented by an increase in venous VEGF blood levels and bioactivity expressed as an increase in ABI. The ABI progressively increased from 0.28 before to 0.56 after gene therapy (weeks refer to time after transfection). This was associated with development of a phasic pulse volume recording compared with nonphasic tracing recorded at baseline. Vertical arrows indicate timing of each of the 2 intramuscular phVEGF165 injections.

View larger version (111K): [in this window] [in a new window]   Figure 5. Limb salvage after gene therapy in a 39-year-old woman (patient 8 and 4, Table). This patient presented with a 3-month history of gangrene of distal one-half of right foot. Although ABI in right limb improved by 0.27, forefoot gangrene was not reversed, and she underwent below-knee amputation. While she was being treated for right limb, however, she developed gangrene of left great toe and shortly after, of 4 remaining left toes as well. After gene transfer to left limb, her ABI increased by 0.22 in association with angiographically demonstrable new collateral vessels. Although she required a great toe amputation, operative site healed promptly, and remaining 4 toes recovered completely, including restoration of normal nail growth.

For the total group of 10 limbs, frequency of ischemic rest pain expressed as afflicted nights per week decreased significantly (5.9±2.1 at baseline versus 1.5±2.8 at 8-week follow-up, P=.043). On the basis of criteria proposed by Rutherford et al,³ limb status improved in 9 of 10 extremities treated (Table). Moderate improvement, including both an upward shift in clinical category (1 clinical category in patients with rest pain and 2 categories in patients with tissue loss) and an increase of >0.1 in the ABI, was documented in 5 patients.

Immunohistochemistry and Molecular Analyses
Tissue specimens retrieved from 1 amputee 10 weeks after gene therapy showed foci of proliferating endothelial cells (Fig 6A). This finding was particularly striking given that endothelial cell proliferation is nearly absent in normal arteries.³⁷ PCR performed on these samples indicated persistence and anatomic redistribution of DNA fragments unique to phVEGF₁₆₅. Noteworthy amplification of DNA fragments was shown in muscle and skin samples derived from the site of injection as well as in several muscle samples remote from the injection site (Fig 6B). Southern blot analysis confirmed persistence of intact plasmid DNA in muscle specimens derived from 2 amputees 8 and 10 weeks after gene therapy (patients 4 and 10, Table) (Fig 6C).

View larger version (52K): [in this window] [in a new window]   Figure 6. Immunohistochemical and molecular analyses of tissue specimens derived from 2 amputees 8 and 10 weeks after gene therapy (limbs 4 and 10, Table). A, Double immunohistochemical staining of tissue specimen with monoclonal antibody to CD31 (brown) and polyclonal antibody to Ki-67 (red) shows proliferating microvascular endothelial cells (arrows). B, PCR demonstrates amplification of phVEGF165 DNA fragments in skin and skeletal muscle specimens. Lane 0 shows 100-bp ladder; lane 2, reaction mixture without tissue DNA; lane 3, negative control (skin specimen from untreated patient); lanes 4 to 6, specimens derived from phVEGF165-treated amputee (patient 4, Table); lane 4, skin; lane 5, gastrocnemius muscle (remote from site of transfection); lane 6, tibialis anterior muscle (transfection site); lane 7, positive control (purified phVEGF165). Amplified fragments had predicted sizes of 300, 338, and 257 bp, spanning the CMV promoter/enhancer region (5'-CCCGACATTGATTATTGA-3' and 5'-CGGGCCATTTACCGTCAT-3'; position 11 to 300), proximal VEGF encoding region and junction between VEGF encoding region and promoter (5'-GCCTTTCTCTCCACAGGT-3' and 5'-GTACTCGATCTCATCAGG-3'; position 861 to 1198), and distal VEGF encoding region and junction between VEGF encoding region and SV40 polyadenylation sequence (5'-CGCGTTGCAAGGCGAGGC-3' and 5'-GGACCCAAAGTGCTCTGC-3'; position 1494 to 1750), respectively. C, Southern blot analysis of EcoR1-digested total cellular DNA (30 µg) (lane 1, patient 4, Table; lanes 2 and 3, patient 10, Table), and 0.5 µg (lane 4) of purified phVEGF165 DNA hybridized with two 32P-labeled phVEGF165 specific probes (position 389 to 1068 and position 991 to 1778) showed persistence of complete plasmid DNA (EcoR1-digested 4703- and 998-bp fragments) in skeletal muscle specimens derived from 2 amputees (patients 4 and 10, Table).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The natural history of critical limb ischemia has been well documented to have an inexorable downhill course.³ The inclusion criteria for this study were drafted to restrict treatment to patients in whom the natural history of critical limb ischemia had been established previously. Seven of the 10 limbs had developed frank gangrene. Although inclusion criteria required a minimum of 4 weeks of conservative measures without evidence of improvement, in reality, signs and/or symptoms of critical limb ischemia had been present in all cases for 2 to 12 months before gene therapy. Among this series of 9 patients (10 limbs), 6 developed critical limb ischemia despite having undergone as many as 7 vascular surgical reconstructions. Seven patients had been specifically advised to undergo limb amputation. All were using analgesic, typically 1 narcotic, medications. Spontaneous resolution of rest pain and/or healing of an ischemic ulcer in patients like these with critical limb ischemia has not to our knowledge been reported previously.¹ Furthermore, because VEGF had not been administered previously as recombinant protein, no data were available from any source to indicate either the safety or bioactivity of any dose of phVEGF₁₆₅. Accordingly, the design of this phase 1 trial, unanimously approved by the Recombinant DNA Advisory Committee and the US Food and Drug Administration, was conducted as a nonrandomized, consecutive treatment series, similar to phase 1 oncology protocols used to study new chemotherapeutic agents administered to human subjects.

Analysis of gene expression at the protein level by use of an ELISA assay for VEGF documented a transient peak of the gene product in the systemic circulation 1 to 3 weeks after gene transfer in 7 patients. Further evidence of gene expression was observed in 6 patients, who developed temporally related peripheral edema, including 2 with bilateral edema. Parenthetically, the latter finding constitutes what is to the best of our knowledge the first demonstration that VEGF may augment vascular permeability in human subjects.

In most patients, treatment was sufficient to achieve clinically significant modulation of the recipient phenotype. Noninvasive studies documented hemodynamic evidence of improved limb perfusion that satisfies outcome criteria proposed to assess the results of surgical reconstruction or percutaneous revascularization.²⁸ Absolute ankle and/or toe pressure increased in 8 limbs after gene therapy (P=.008). ABI and/or TBI increased from 0.33±0.05 at baseline to 0.48±0.03 at 12 weeks (P=.017). To put this in perspective, an increase of >0.1 in the ABI is considered indicative of a successful surgical or percutaneous intervention.²⁸ To the best of our knowledge, such improvement has not previously been achieved spontaneously or with medical therapy in patients with critical limb ischemia.

Similarly, angiographic demonstration of newly visible collateral vessels, accompanied here by noninvasive (MRA) evidence of improved blood flow, has to the best of our knowledge not been reported previously in response to any therapeutic intervention. Indeed, previous reports have indicated that current methods used to perform diagnostic contrast angiography cannot provide images of arteries measuring <200 µm in diameter³⁸ ; the spatial resolution of images obtained by MRA is even less. Using synchrotron radiation microangiography to assess collateral artery development after VEGF gene transfer in a rat model of hindlimb ischemia, Takeshita et al³⁸ showed that neovascularization included a substantial contribution of vessels <180 µm in diameter. Thus, conventional angiographic techniques used in the present study may have failed to depict the full extent of angiogenesis achieved after phVEGF₁₆₅ transfection, particularly given that most newly visible collaterals were diminutive (200 to 800 µm).

That angiogenesis was in fact therapeutic in the present investigation was shown by concomitant reduction in rest pain and/or a favorable impact on limb integrity. Rest pain resolved in all 3 of the patients who presented with rest pain alone. Ischemic ulcers present in 7 limbs healed or improved markedly in 4 patients; this included 3 patients recommended for below-knee amputation in whom successful limb salvage was achieved. Given the poor prognosis for patients with chronic critical limb ischemia, in whom the possibility of spontaneous improvement is remote,^{1 2} the outcome in this initial cohort is thus encouraging.

Beginning with the reports of Wolff et al,³⁹ work from several laboratories^{40 41 42 43 44 45 46 47 48} convincingly demonstrated evidence of transgene expression after direct injection of nonviral, covalently closed pDNA into skeletal muscle. The conceptual basis for therapeutic angiogenesis after phVEGF₁₆₅ gene transfer in particular has been established previously by our laboratory.^{49 50} The results of the present trial extend previous findings from studies performed in live animals⁴⁶ to patients with advanced peripheral artery disease.

The failure of previous gene therapy trials to yield evidence of clinical success has been attributed to gene delivery, specifically the inability to deliver genes efficiently and to obtain sustained expression.⁵¹ Those cases in which phVEGF₁₆₅ gene therapy led to successful clinical outcomes in this clinical trial suggest that the success of gene therapy is not solely a function of transfection efficiency, nor is it necessarily dependent on protracted gene expression. Several aspects of the gene, protein, and target tissue may have contributed to successful modulation of the host phenotype, despite the relatively low transfection efficiency typically associated with naked DNA. First, VEGF, as noted above, is actively secreted by intact cells; previous studies in our laboratory⁵² have documented that genes that encode for secreted proteins, as opposed to proteins that remain intracellular, may yield meaningful biological outcomes because of paracrine effects of the secreted gene product. Second, heparin avidity of the VEGF₁₆₅ isoform promotes binding to cell surface and matrix heparan sulfates that may create a biological reservoir of the secreted protein, enhancing the temporal opportunity for bioactivity. Third, although endothelial cells were previously viewed solely as the target for VEGF, it is now clear that endothelial cells subjected to hypoxia can synthesize VEGF as well.⁵³ This autocrine feature of VEGF creates the opportunity for amplifying the effects of even a small amount of exogenous VEGF, because endothelial cell proliferation in the ischemic territory creates additional potential cellular sources of VEGF synthesis and secretion. Fourth, VEGF inhibits apoptosis,⁵⁴ in part by upregulating endothelial cell expression of fibronectin and _vß₃,^{54 55} thus preserving the survival signal generated by attachment of endothelial cells to their extracellular matrix. Such reduction in endothelial cell apoptosis would be expected to complement the mitogenic effect of VEGF, resulting in a further net increase in endothelial cell viability. Fifth, with regard to the target of gene therapy, it has been noted^{14 26 49} that VEGF-induced angiogenesis is not indiscriminate or widespread but rather is restricted to sites of ischemia. This appears to result from paracrine upregulation of the principal high-affinity VEGF receptor (Kdr) in response to factors released from hypoxic skeletal myocytes.⁵⁶ Receptor upregulation on endothelial cells within the region of lower-limb or myocardial ischemia thus enables these cells to act as magnets for any VEGF secreted into the ischemic milieu. Finally, the fact that the host tissues are by definition hypoxic may directly aid intramuscular transfer of naked DNA, because transfection efficiency is augmented when the injected skeletal muscle is ischemic.^{40 46}

Previous work from our laboratory established that phVEGF₁₆₅ transgene expression is limited to <30 days in animal models of limb ischemia.^{26 46 49} Although Southern blot and PCR analyses indicated that small amounts of plasmid DNA were preserved in tissue specimens derived from 2 amputees in this clinical trial, we have no evidence to suggest that transgene expression is more protracted in human subjects than in our animal models. Fortuitously, however, it appears that in both animals and humans, collateral vessel development sufficient to restore limb perfusion to satisfactory resting levels occurs within this time interval. Cessation of gene expression beyond this time point can be considered to constitute an inherent safety feature of phVEGF₁₆₅ gene transfer that protects the organism from indefinite constitutive expression of an angiogenic growth factor.

Several caveats regarding this preliminary clinical experience must be acknowledged. First, it is theoretically possible that VEGF expression resulting from gene transfer could promote the development of a tumor that is currently too small to be recognized. Previous laboratory studies, however, have established that VEGF expression, although sufficient to promote a growth process, did not lead to malignant proliferation or to metastasis, a finding in agreement with the notion that stimulation of angiogenesis is necessary but not sufficient for malignant growth.^{34 57} It is also theoretically possible that VEGF may aggravate deteriorating eyesight due to diabetic retinopathy.³³ To date, however, no change in visual acuity has been observed in any patient treated with phVEGF₁₆₅ gene transfer. Nevertheless, these findings are preliminary and do not establish the long-term safety of VEGF, administered either as a gene or gene product. Second, although it is conceivable that continuous, predominantly local production of VEGF resulting from the transgene may be preferable, from the standpoints of both safety and efficacy, to a single larger dose of recombinant protein, this notion remains to be proven. Preliminary clinical trials of recombinant VEGF protein therapy have confirmed that mild hypotension seen in preclinical studies^{15 58} may be seen in humans as well (unpublished data). Presumably, the route and/or dose of recombinant protein delivery can be adjusted to address this issue. Clearly, further clinical studies of both recombinant protein and alternative dosing regimens of gene therapy will be required to define the relative merits of each approach. Third, we cannot exclude the possibility that these encouraging preliminary results might have been made more substantial and/or uniform by the use of alternative vector systems and/or dosing strategies.^{45 48 51 59}

In summary, these preliminary data may be cautiously interpreted to support both the strategy of intramuscular gene therapy and the concept of therapeutic angiogenesis for treatment of selected patients with critical limb ischemia.

	Selected Abbreviations and Acronyms

 

ABI = ankle-brachial index MRA = magnetic resonance angiography PCR = polymerase chain reaction phVEGF165 = plasmid encoding 165-amino-acid isoform of human VEGF TBI = toe-brachial index VEGF = vascular endothelial growth factor

	Acknowledgments

 
This study was supported in part by an Academic Award in Vascular Medicine (HL-02824) and grants HL-53354 and HL-57516 (Dr Isner) and AR-40197 and HL-50692 (Dr Walsh) from the National Institutes of Health, Bethesda, Md, and the E.L. Wiegand Foundation, Reno, Nev. Dr Baumgartner is the recipient of a Swiss National Science Foundation grant.

Received October 9, 1997; revision received December 22, 1997; accepted January 13, 1998.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. European Working Group on Critical Leg Ischemia. Second European consensus document on chronic critical leg ischemia. Circulation. 1991;84(suppl IV):IV-1–IV-26.

2. Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery P, Bousser MG, Clement D, Coffman J, Deutschinoff A, Bletry O, Hampton J, Hahler F, Ohlin P, Rieger H, Stranden E, Turpie AGG, Urai L, Verstraete M. Fate of the patient with chronic leg ischaemia. J Cardiovasc Surg. 1989;1:50–57.

3. Rutherford RB, Flanigan DP, Gupta SK, Johnston KW, Karmondy A, Whittemore AD, Baker D, Ernst CB, Jamieson C, Mehta S. Suggested standards for reports dealing with lower extremity ischemia. Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg. 1986;4:80–94.[Medline] [Order article via Infotrieve]

4. Albers M, Fratezi AC, DeLuccia N. Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease. J Vasc Surg. 1992;16:54–59.[Medline] [Order article via Infotrieve]

5. Isner JM, Rosenfield K. Redefining the treatment of peripheral artery disease. Circulation. 1993;88:1534–1557.[Free Full Text]

6. Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care. 1983;6:87–91.[Abstract]

7. Taylor LM Jr, Porter JM. Natural history and non-operative treatment of chronic lower extremity ischemia. In: Rutherford RB, ed. Vascular Surgery. Philadelphia, Pa: WB Saunders; 1989:656.

8. Wolfe JHN. Defining the outcome of critical ischemia: a one year prospective study. Br J Surg. 1986;73:321–328.

9. Eneroth M, Persson BM. Amputation for occlusive arterial disease: a multicenter study of 177 amputees. Int Orthop. 1992;16:382–387.

10. Campbell WB, Johnston JA, Kernick VF, Rutter EA. Lower limb amputation: striking the balance. Ann R Coll Surg Engl. 1994;76:205–209.[Medline] [Order article via Infotrieve]

11. Dawson I, Keller BP, Brand R, Pesch-Batenburg J, Hajo van Bockel J. Late outcomes of limb loss after failed infrainguinal bypass. J Vasc Surg. 1995;21:613–622.[Medline] [Order article via Infotrieve]

12. Skinner JA, Cohen AT. Amputation for premature peripheral atherosclerosis: do young patients do better? Lancet. 1996;348:1396.

13. Baffour R, Berman J, Garb JL, Rhee SW, Kaufman J, Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg. 1992;16:181–191.[Medline] [Order article via Infotrieve]

14. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis: a single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. J Clin Invest. 1994;93:662–670.

15. Hariawala M, Horowitz JR, Esakof D, Sheriff DD, Walter DH, Chaudhry GM, Desai V, Keyt B, Isner JM, Symes JF. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res. 1996;63:77–82.[Medline] [Order article via Infotrieve]

16. Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, Unger EF. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation. 1994;89:2183–2189.[Abstract/Free Full Text]

17. Pearlman JD, Hibberd MG, Chuang ML, Harada K, Lopez JJ, Gladston SR, Friedman M, Sellke FW, Simons M. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med. 1995;1:1085–1089.[Medline] [Order article via Infotrieve]

18. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983–985.[Abstract/Free Full Text]

19. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309.[Abstract/Free Full Text]

20. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309–1312.[Abstract/Free Full Text]

21. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J. 1989;8:3801–3806.[Medline] [Order article via Infotrieve]

22. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851–855.[Medline] [Order article via Infotrieve]

23. D'Amore PA, Thompson RW. Mechanisms of angiogenesis. Annu Rev Physiol. 1987;49:453–464.[Medline] [Order article via Infotrieve]

24. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931–10934.[Free Full Text]

25. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671–674.[Medline] [Order article via Infotrieve]

26. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes J. Clinical evidence of angiogenesis following arterial gene transfer of phVEGF₁₆₅. Lancet. 1996;348:370–374.[Medline] [Order article via Infotrieve]

27. Standards of Practice Committee of the Society of Cardiovascular and Interventional Radiology. Guidelines for percutaneous transluminal angioplasty. J Vasc Interv Radiol. 1990;1:5–13.

28. Rutherford RB, Becker GJ. Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. Radiology. 1991;181:277–281.[Abstract/Free Full Text]

29. Tischer E, Mitchell R, Hartmann T, Silva M, Gospodarowicz D, Fiddes J, Abraham J. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991;266:11947–11954.[Abstract/Free Full Text]

30. Summer DS, Thiele BI. The vascular laboratory. In: Rutherford RB, ed. Vascular Surgery. Philadelphia, Pa: WB Saunders; 1995:45–64.

31. Owen RS, Carpenter JP, Baum RA, Perloff LJ, Cope C. Magnetic resonance imaging of angiographically occult runoff vessels in peripheral arterial occlusive disease. N Engl J Med. 1992;326:1577–1581.[Abstract]

32. Couffinhal T, Kearney M, Witzenbichler B, Chen D, Murohara T, Losordo DW, Symes JF, Isner JM. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol. 1997;150:1673–1685.[Abstract]

33. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Theme H, Iwamoto MA, Parke JE, Nguyen MD, Aiello LM, Ferrara N, King GL. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–1487.[Abstract/Free Full Text]

34. Ferrara N, Winer J, Burton T, Rowland A, Siegel M, Phillips HS, Terrell T, Keller GA, Levinson AD. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J Clin Invest. 1992;91:160–170.

35. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029–1039.[Abstract]

36. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP, and the Vascular Clinical Trialists. Clinical trials for claudication assessment of exercise performance, functional status, and clinical end points. Circulation. 1995;92:614–621.[Free Full Text]

37. Schaper W, Brahander MD, Lewi P. DNA synthesis and mitoses in coronary collateral vessels of the dog. Circ Res. 1971;28:671–679.[Abstract/Free Full Text]

38. Takeshita S, Isshiki T, Tanaka E, Eto K, Miyazawa Y, Tanaka A, Shinozaki Y, Hyodo K, Ando M, Kubota M, Tanioka K, Umetani K, Ochiai M, Sato T, Mori H, Miyashita H. Use of synchrotron radiation microangiography to assess development of small collateral arteries in a rat model of hindlimb ischemia. Circulation. 1997;95:805–808.[Abstract/Free Full Text]

39. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465–1468.[Abstract/Free Full Text]

40. Takeshita S, Isshiki T, Sato T. Increased expression of direct gene transfer into skeletal muscles observed after acute ischemic injury in rats. Lab Invest. 1996;74:1061–1065.[Medline] [Order article via Infotrieve]

41. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest. 1992;90:626–630.

42. Manthorpe M, Cornefert-Jensen F, Hartikka J, Felgner J, Rundell A, Margalith M, Dwarki V. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum Gene Ther. 1993;4:419–431.[Medline] [Order article via Infotrieve]

43. Davis HL, Whalen RG, Demeneix BA. Direct gene transfer into skeletal muscle in vivo. Hum Gene Ther. 1993;4:151–159.[Medline] [Order article via Infotrieve]

44. Vitadello M, Schiaffino M, Picard A, Scarpa M, Schiaffino S. Gene transfer in regenerating muscle. Hum Gene Ther. 1994;5:11–18.[Medline] [Order article via Infotrieve]

45. Levy MY, Barron LG, Meyer KB, Szoka FC. Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Gene Ther. 1996;3:201–211.[Medline] [Order article via Infotrieve]

46. Tsurumi Y, Takeshita S, Chen D, Kearney M, Rossow ST, Passeri J, Horowitz JR, Symes JF. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation. 1996;94:3281–3290.[Abstract/Free Full Text]

47. Tripathy SK, Svensson EC, Black HB, Goldwasser E, Margalith M, Hobart PM, Leiden JM. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci U S A. 1996;93:10876–10880.[Abstract/Free Full Text]

48. Hartikka J, Sawdey M, Cornefert-Jensen F, Margalith M, Barnhart K, Nolasco M, Vahlsing L, Meek J, Marquet M, Hobart P, Norman J, Manthorpe M. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther. 1996;7:1205–1217.[Medline] [Order article via Infotrieve]

49. Takeshita S, Tsurumi Y, Couffinhal T, Asahara T, Bauters C, Symes JF, Ferrara N, Isner JM. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest. 1996;75:487–502.[Medline] [Order article via Infotrieve]

50. Takeshita S, Weir L, Chen D, Zheng LP, Riessen R, Bauters C, Symes JF, Ferrara N, Isner JM. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun. 1996;227:628–635.[Medline] [Order article via Infotrieve]

51. Verma IM, Somia N. Gene therapy: promises, problems, and prospects. Nature. 1997;389:239–242.[Medline] [Order article via Infotrieve]

52. Losordo DW, Pickering JG, Takeshita S, Leclerc G, Gal D, Weir L, Kearney M, Jekanowski J, Isner JM. Use of the rabbit ear artery to serially assess foreign protein secretion after site specific arterial gene transfer in vivo: evidence that anatomic identification of successful gene transfer may underestimate the potential magnitude of transgene expression. Circulation. 1994;89:785–792.[Abstract/Free Full Text]

53. Namiki A, Brogi E, Kearney M, Wu T, Couffinhal T, Varticovski L, Isner JM. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem. 1995;270:31189–31195.[Abstract/Free Full Text]

54. Spyridopoulos I, Brogi E, Kearney M, Sullivan AB, Cetrulo C, Isner JM, Losordo DW. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. J Mol Cell Cardiol. 1997;29:1321–1330.[Medline] [Order article via Infotrieve]

55. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Perruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the avb3 integrin, osteopontin, and thrombin. Am J Pathol. 1996;149:293–305.[Abstract]

56. Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L, Keyt B, Isner JM. Hypoxia-induced paracrine regulation of VEGF receptor expression. J Clin Invest. 1996;97:469–476.[Medline] [Order article via Infotrieve]

57. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186.

58. Horowitz JR, Rivard A, van der Zee R, Hariawala MD, Sheriff DD, Esakof DD, Chaudhry M, Symes JF, Isner JM. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Arterioscler Thromb Vasc Biol. 1997;17:2793–2800.[Abstract/Free Full Text]

59. Leiden JM. Gene therapy: promise, pitfalls, and prognosis. N Engl J Med. 1995;333:871–873.[Free Full Text]

This article has been cited by other articles:

				D. M. Birk, J. Barbato, L. Mureebe, and R. A. Chaer Basic Science Review: Current Insights on the Biology and Clinical Aspects of VEGF Regulation Vascular and Endovascular Surgery, December 1, 2009; 42(6): 517 - 530. [Abstract] [PDF]

				M. Kubo, K. Egashira, T. Inoue, J.-i. Koga, S. Oda, L. Chen, K. Nakano, T. Matoba, Y. Kawashima, K. Hara, et al. Therapeutic Neovascularization by Nanotechnology-Mediated Cell-Selective Delivery of Pitavastatin Into the Vascular Endothelium Arterioscler. Thromb. Vasc. Biol., June 1, 2009; 29(6): 796 - 801. [Abstract] [Full Text] [PDF]

				D. Zimpfer, S. Aharinejad, J. Holfeld, A. Thomas, J. Dumfarth, R. Rosenhek, M. Czerny, W. Schaden, M. Gmeiner, E. Wolner, et al. Direct epicardial shock wave therapy improves ventricular function and induces angiogenesis in ischemic heart failure J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 963 - 970. [Abstract] [Full Text] [PDF]

				F. Sanada, Y. Taniyama, J. Azuma, K. Iekushi, N. Dosaka, T. Yokoi, N. Koibuchi, H. Kusunoki, Y. Aizawa, and R. Morishita Hepatocyte Growth Factor, but not Vascular Endothelial Growth Factor, Attenuates Angiotensin II-Induced Endothelial Progenitor Cell Senescence Hypertension, January 1, 2009; 53(1): 77 - 82. [Abstract] [Full Text] [PDF]

				M. C. van Oostrom, O. van Oostrom, P. H. A. Quax, M. C. Verhaar, and I. E. Hoefer Insights into mechanisms behind arteriogenesis: what does the future hold? J. Leukoc. Biol., December 1, 2008; 84(6): 1379 - 1391. [Abstract] [Full Text] [PDF]

				A. J.G. Horrevoets Kallikrein teams up with GSK-3{beta} in heart failure prevention Cardiovasc Res, December 1, 2008; 80(3): 328 - 329. [Full Text] [PDF]

				K. R. Cho, J.-S. Choi, W. Hahn, D. S. Kim, J. S. Park, D. S. Lee, and K.-B. Kim Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model Eur. J. Cardiothorac. Surg., October 1, 2008; 34(4): 857 - 863. [Abstract] [Full Text] [PDF]

				S. Sato, Y. Nitta, Y. Saiki, S. Kawamoto, A. Iguchi, M. Kaku, Y. Tabata, and K. Tabayashi Enhanced Perigraft Angiogenesis Prevents Prosthetic Graft Infection Ann. Thorac. Surg., October 1, 2008; 86(4): 1278 - 1284. [Abstract] [Full Text] [PDF]

				J. Tongers, J. G. Roncalli, and D. W. Losordo Therapeutic Angiogenesis for Critical Limb Ischemia: Microvascular Therapies Coming of Age Circulation, July 1, 2008; 118(1): 9 - 16. [Full Text] [PDF]

				R. J. Powell, M. Simons, F. O. Mendelsohn, G. Daniel, T. D. Henry, M. Koga, R. Morishita, and B. H. Annex Results of a Double-Blind, Placebo-Controlled Study to Assess the Safety of Intramuscular Injection of Hepatocyte Growth Factor Plasmid to Improve Limb Perfusion in Patients With Critical Limb Ischemia Circulation, July 1, 2008; 118(1): 58 - 65. [Abstract] [Full Text] [PDF]

				Z. Sun, J. Wu, H. Fujii, J. Wu, S.-H. Li, S. Porozov, A. Belleli, V. Fulga, Y. Porat, and R.-K. Li Human angiogenic cell precursors restore function in the infarcted rat heart: A comparison of cell delivery routes Eur J Heart Fail, June 1, 2008; 10(6): 525 - 533. [Abstract] [Full Text] [PDF]

				C Kalka and I. Baumgartner Gene and stem cell therapy in peripheral arterial occlusive disease Vascular Medicine, May 1, 2008; 13(2): 157 - 172. [Abstract] [PDF]

				N. R. Sodha, M. Boodhwani, R. T. Clements, S.-H. Xu, K. R. Khabbaz, and F. W. Sellke Increased Antiangiogenic Protein Expression in the Skeletal Muscle of Diabetic Swine and Patients Arch Surg, May 1, 2008; 143(5): 463 - 470. [Abstract] [Full Text] [PDF]

				T. Urano, Y. Ito, M. Akao, T. Sawa, K. Miyata, M. Tabata, T. Morisada, T. Hato, M. Yano, T. Kadomatsu, et al. Angiopoietin-Related Growth Factor Enhances Blood Flow Via Activation of the ERK1/2-eNOS-NO Pathway in a Mouse Hind-Limb Ischemia Model Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 827 - 834. [Abstract] [Full Text] [PDF]

				D. Ricci, A. A. Mennander, L. D. Pham, V. P. Rao, N. Miyagi, G. W. Byrne, S. J. Russell, and C. G.A. McGregor Non-invasive radioiodine imaging for accurate quantitation of NIS reporter gene expression in transplanted hearts Eur. J. Cardiothorac. Surg., January 1, 2008; 33(1): 32 - 39. [Abstract] [Full Text] [PDF]

				Y. Takaoka, M. Ohta, A. Ito, K. Takamatsu, A. Sugano, K. Funakoshi, N. Takaoka, N. Sato, H. Yokozaki, N. Arizono, et al. Electroacupuncture suppresses myostatin gene expression: cell proliferative reaction in mouse skeletal muscle Physiol Genomics, July 18, 2007; 30(2): 102 - 110. [Abstract] [Full Text] [PDF]

				S. M. Vartanian and R. Sarkar Therapeutic Angiogenesis Vascular and Endovascular Surgery, July 1, 2007; 41(3): 173 - 185. [Abstract] [PDF]

				V. L.T. Ballard and J. M. Edelberg Stem Cells and the Regeneration of the Aging Cardiovascular System Circ. Res., April 27, 2007; 100(8): 1116 - 1127. [Abstract] [Full Text] [PDF]

				S. Yla-Herttuala, T. T. Rissanen, I. Vajanto, and J. Hartikainen Vascular Endothelial Growth Factors: Biology and Current Status of Clinical Applications in Cardiovascular Medicine J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1015 - 1026. [Abstract] [Full Text] [PDF]

				N. Inoue, T. Kondo, K. Kobayashi, M. Aoki, Y. Numaguchi, M. Shibuya, and T. Murohara Therapeutic Angiogenesis Using Novel Vascular Endothelial Growth Factor-E/Human Placental Growth Factor Chimera Genes Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 99 - 105. [Abstract] [Full Text] [PDF]

				A. T. Hirsch Critical Limb Ischemia and Stem Cell Research: Anchoring Hope With Informed Adverse Event Reporting Circulation, December 12, 2006; 114(24): 2581 - 2583. [Full Text] [PDF]

				Z. W. Zhuang, L. Gao, M. Murakami, J. D. Pearlman, T. J. Sackett, M. Simons, and E. D. de Muinck Arteriogenesis: Noninvasive Quantification with Multi-Detector Row CT Angiography and Three-dimensional Volume Rendering in Rodents Radiology, September 1, 2006; 240(3): 698 - 707. [Abstract] [Full Text] [PDF]

				A. W.Y. Chung, Y. N. Hsiang, L. A. Matzke, B. M. McManus, C. van Breemen, and E. B. Okon Reduced Expression of Vascular Endothelial Growth Factor Paralleled With the Increased Angiostatin Expression Resulting From the Upregulated Activities of Matrix Metalloproteinase-2 and -9 in Human Type 2 Diabetic Arterial Vasculature Circ. Res., July 21, 2006; 99(2): 140 - 148. [Abstract] [Full Text] [PDF]

				K. Kobayashi, T. Kondo, N. Inoue, M. Aoki, M. Mizuno, K. Komori, J. Yoshida, and T. Murohara Combination of In Vivo Angiopoietin-1 Gene Transfer and Autologous Bone Marrow Cell Implantation for Functional Therapeutic Angiogenesis Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1465 - 1472. [Abstract] [Full Text] [PDF]

				J. Emmerich Current State and Perspective on Medical Treatment of Critical Leg Ischemia: Gene and Cell Therapy International Journal of Lower Extremity Wounds, December 1, 2005; 4(4): 234 - 241. [Abstract] [PDF]

				R. Morishita, M. Aoki, and T. Ogihara Does gene therapy become pharmacotherapy? Exp Physiol, May 1, 2005; 90(3): 307 - 313. [Abstract] [Full Text] [PDF]

				Y.-s. Yoon, S. Uchida, O. Masuo, M. Cejna, J.-S. Park, H.-c. Gwon, R. Kirchmair, F. Bahlman, D. Walter, C. Curry, et al. Progressive Attenuation of Myocardial Vascular Endothelial Growth Factor Expression Is a Seminal Event in Diabetic Cardiomyopathy: Restoration of Microvascular Homeostasis and Recovery of Cardiac Function in Diabetic Cardiomyopathy After Replenishment of Local Vascular Endothelial Growth Factor Circulation, April 26, 2005; 111(16): 2073 - 2085. [Abstract] [Full Text] [PDF]

				K.-H. Lee, K.-H. Jung, S.-H. Song, D. H. Kim, B. C. Lee, H. J. Sung, Y.-M. Han, Y. S. Choe, D. Y. Chi, and B.-T. Kim Radiolabeled RGD Uptake and {alpha}v Integrin Expression Is Enhanced in Ischemic Murine Hindlimbs J. Nucl. Med., March 1, 2005; 46(3): 472 - 478. [Abstract] [Full Text] [PDF]

				O. Suda, L. A. Smith, L. V. d'Uscio, T. E. Peterson, and Z. S. Katusic In Vivo Expression of Recombinant Vascular Endothelial Growth Factor in Rabbit Carotid Artery Increases Production of Superoxide Anion Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): 506 - 511. [Abstract] [Full Text] [PDF]

				P. Coats and R. Wadsworth Marriage of resistance and conduit arteries breeds critical limb ischemia Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1044 - H1050. [Abstract] [Full Text] [PDF]

				I. Baumgartner, H. C. Thoeny, O. Kummer, C. Roefke, C. Skjelsvik, C. Boesch, and R. Kreis Leg Ischemia: Assessment with MR Angiography and Spectroscopy Radiology, March 1, 2005; 234(3): 833 - 841. [Abstract] [Full Text] [PDF]

				M. E. Gerritsen HGF and VEGF: A Dynamic Duo Circ. Res., February 18, 2005; 96(3): 272 - 273. [Full Text] [PDF]

				J.-K. Min, Y.-M. Lee, J. H. Kim, Y.-M. Kim, S. W. Kim, S.-Y. Lee, Y. S. Gho, G. T. Oh, and Y.-G. Kwon Hepatocyte Growth Factor Suppresses Vascular Endothelial Growth Factor-Induced Expression of Endothelial ICAM-1 and VCAM-1 by Inhibiting the Nuclear Factor-{kappa}B Pathway Circ. Res., February 18, 2005; 96(3): 300 - 307. [Abstract] [Full Text] [PDF]

				A. Chandiwal, V. Balasubramanian, Z. K. Baldwin, M. S. Conte, and L. B. Schwartz Gene Therapy for the Extension of Vein Graft Patency: A Review Vascular and Endovascular Surgery, January 1, 2005; 39(1): 1 - 14. [Abstract] [PDF]

				Y. Wang, E. Kilic, U. Kilic, B. Weber, C. L. Bassetti, H. H. Marti, and D. M. Hermann VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena Brain, January 1, 2005; 128(1): 52 - 63. [Abstract] [Full Text] [PDF]

				J. F. Arenillas, J. Alvarez-Sabin, J. Montaner, A. Rosell, C. A. Molina, A. Rovira, M. Ribo, E. Sanchez, and M. Quintana Angiogenesis in Symptomatic Intracranial Atherosclerosis: Predominance of the Inhibitor Endostatin Is Related to a Greater Extent and Risk of Recurrence Stroke, January 1, 2005; 36(1): 92 - 97. [Abstract] [Full Text] [PDF]

				W. Li, K. Tanaka, A. Ihaya, Y. Fujibayashi, S. Takamatsu, K. Morioka, M. Sasaki, T. Uesaka, T. Kimura, N. Yamada, et al. Gene therapy for chronic myocardial ischemia using platelet-derived endothelial cell growth factor in dogs Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H408 - H415. [Abstract] [Full Text] [PDF]

				A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn Vascular Endothelial Growth Factor and Angiogenesis Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580. [Abstract] [Full Text] [PDF]

				K. Yamamoto, T. Kondo, S. Suzuki, H. Izawa, M. Kobayashi, N. Emi, K. Komori, T. Naoe, J. Takamatsu, and T. Murohara Molecular Evaluation of Endothelial Progenitor Cells in Patients With Ischemic Limbs: Therapeutic Effect by Stem Cell Transplantation Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): e192 - e196. [Abstract] [Full Text] [PDF]

				T. Nishida, H. Shimokawa, K. Oi, H. Tatewaki, T. Uwatoku, K. Abe, Y. Matsumoto, N. Kajihara, M. Eto, T. Matsuda, et al. Extracorporeal Cardiac Shock Wave Therapy Markedly Ameliorates Ischemia-Induced Myocardial Dysfunction in Pigs in Vivo Circulation, November 9, 2004; 110(19): 3055 - 3061. [Abstract] [Full Text] [PDF]

				M. Aoki, M. Yasutake, and T. Murohara Derivation of Functional Endothelial Progenitor Cells from Human Umbilical Cord Blood Mononuclear Cells Isolated by a Novel Cell Filtration Device Stem Cells, November 1, 2004; 22(6): 994 - 1002. [Abstract] [Full Text] [PDF]

				Q. Dai, J. Huang, B. Klitzman, C. Dong, P. J. Goldschmidt-Clermont, K. L. March, J. Rokovich, B. Johnstone, E. J. Rebar, S. K. Spratt, et al. Engineered Zinc Finger-Activating Vascular Endothelial Growth Factor Transcription Factor Plasmid DNA Induces Therapeutic Angiogenesis in Rabbits With Hindlimb Ischemia Circulation, October 19, 2004; 110(16): 2467 - 2475. [Abstract] [Full Text] [PDF]

				E. R. Schwarz, D. A. Meven, N. Z. Sulemanjee, P. H. Kersting, T. Tussing, E. C. Skobel, P. Hanrath, and B. F. Uretsky Monocyte Chemoattractant Protein 1-Induced Monocyte Infiltration Produces Angiogenesis but Not Arteriogenesis in Chronically Infarcted Myocardium Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2004; 9(4): 279 - 289. [Abstract] [PDF]

				N. Ferrara Vascular Endothelial Growth Factor: Basic Science and Clinical Progress Endocr. Rev., August 1, 2004; 25(4): 581 - 611. [Abstract] [Full Text] [PDF]

				R. J Powell, J. Dormandy, M. Simons, R. Morishita, and B. H Annex Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial Vascular Medicine, August 1, 2004; 9(3): 193 - 198. [Abstract] [PDF]

				P.A Dijkmans, L.J.M Juffermans, R.J.P Musters, A van Wamel, F.J ten Cate, W van Gilst, C.A Visser, N de Jong, and O Kamp Microbubbles and ultrasound: from diagnosis to therapy Eur J Echocardiogr, August 1, 2004; 5(4): 245 - 246. [Abstract] [Full Text] [PDF]

				R. Morishita, M. Aoki, N. Hashiya, H. Makino, K. Yamasaki, J. Azuma, Y. Sawa, H. Matsuda, Y. Kaneda, and T. Ogihara Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial Disease Hypertension, August 1, 2004; 44(2): 203 - 209. [Abstract] [Full Text] [PDF]

				V. van Weel, M. M.L. Deckers, J. M. Grimbergen, K. J.M. van Leuven, J. H.P. Lardenoye, R. O. Schlingemann, G. P. van Nieuw Amerongen, J. H. van Bockel, V. W.M. van Hinsbergh, and P. H.A. Quax Vascular Endothelial Growth Factor Overexpression in Ischemic Skeletal Muscle Enhances Myoglobin Expression In Vivo Circ. Res., July 9, 2004; 95(1): 58 - 66. [Abstract] [Full Text] [PDF]

				C. L. Duvall, W. Robert Taylor, D. Weiss, and R. E. Guldberg Quantitative microcomputed tomography analysis of collateral vessel development after ischemic injury Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H302 - H310. [Abstract] [Full Text] [PDF]

				N. Hashiya, N. Jo, M. Aoki, K. Matsumoto, T. Nakamura, Y. Sato, N. Ogata, T. Ogihara, Y. Kaneda, and R. Morishita In Vivo Evidence of Angiogenesis Induced by Transcription Factor Ets-1: Ets-1 Is Located Upstream of Angiogenesis Cascade Circulation, June 22, 2004; 109(24): 3035 - 3041. [Abstract] [Full Text] [PDF]

				C. Theopold, F. Yao, and E. Eriksson Gene Therapy in the Treatment of Lower Extremity Wounds International Journal of Lower Extremity Wounds, June 1, 2004; 3(2): 69 - 79. [Abstract] [PDF]

				L. Ye, H. K Haider, S.-J. Jiang, and E. K. Sim Therapeutic Angiogenesis Using Vascular Endothelial Growth Factor Asian Cardiovasc Thorac Ann, June 1, 2004; 12(2): 173 - 181. [Abstract] [Full Text] [PDF]

				D. W. Losordo and S. Dimmeler Therapeutic Angiogenesis and Vasculogenesis for Ischemic Disease: Part I: Angiogenic Cytokines Circulation, June 1, 2004; 109(21): 2487 - 2491. [Full Text] [PDF]

				X.-Y. Zhu, M. Rodriguez-Porcel, M. D. Bentley, A. R. Chade, V. Sica, C. Napoli, N. Caplice, E. L. Ritman, A. Lerman, and L. O. Lerman Antioxidant Intervention Attenuates Myocardial Neovascularization in Hypercholesterolemia Circulation, May 4, 2004; 109(17): 2109 - 2115. [Abstract] [Full Text] [PDF]

				R. Kirchmair, R. Gander, M. Egger, A. Hanley, M. Silver, A. Ritsch, T. Murayama, N. Kaneider, W. Sturm, M. Kearny, et al. The Neuropeptide Secretoneurin Acts as a Direct Angiogenic Cytokine In Vitro and In Vivo Circulation, February 17, 2004; 109(6): 777 - 783. [Abstract] [Full Text] [PDF]

				M. Sugano, K. Tsuchida, and N. Makino Intramuscular Gene Transfer of Soluble Tumor Necrosis Factor-{alpha} Receptor 1 Activates Vascular Endothelial Growth Factor Receptor and Accelerates Angiogenesis in a Rat Model of Hindlimb Ischemia Circulation, February 17, 2004; 109(6): 797 - 802. [Abstract] [Full Text] [PDF]

				V. Lambert, R. Michel, G.-M. Mazmanian, E. M. Dulmet, A. Capderou, P. Herve, C. Planche, and A. Serraf Induction of pulmonary angiogenesis by adenoviral-mediated gene transfer of vascular endothelial growth factor Ann. Thorac. Surg., February 1, 2004; 77(2): 458 - 463. [Abstract] [Full Text] [PDF]

				P. Y. Takahashi, L. J. Kiemele, and J. P. Jones Jr Wound Care for Elderly Patients: Advances and Clinical Applications for Practicing Physicians Mayo Clin. Proc., February 1, 2004; 79(2): 260 - 267. [Abstract] [PDF]

				M. Shimamura, N. Sato, K. Oshima, M. Aoki, H. Kurinami, S. Waguri, Y. Uchiyama, T. Ogihara, Y. Kaneda, and R. Morishita Novel Therapeutic Strategy to Treat Brain Ischemia: Overexpression of Hepatocyte Growth Factor Gene Reduced Ischemic Injury Without Cerebral Edema in Rat Model Circulation, January 27, 2004; 109(3): 424 - 431. [Abstract] [Full Text] [PDF]

				K. Hiraoka, H. Koike, S. Yamamoto, N. Tomita, C. Yokoyama, T. Tanabe, T. Aikou, T. Ogihara, Y. Kaneda, and R. Morishita Enhanced Therapeutic Angiogenesis by Cotransfection of Prostacyclin Synthase Gene or Optimization of Intramuscular Injection of Naked Plasmid DNA Circulation, November 25, 2003; 108(21): 2689 - 2696. [Abstract] [Full Text] [PDF]

				T. Namba, H. Koike, K. Murakami, M. Aoki, H. Makino, N. Hashiya, T. Ogihara, Y. Kaneda, M. Kohno, and R. Morishita Angiogenesis Induced by Endothelial Nitric Oxide Synthase Gene Through Vascular Endothelial Growth Factor Expression in a Rat Hindlimb Ischemia Model Circulation, November 4, 2003; 108(18): 2250 - 2257. [Abstract] [Full Text] [PDF]

				V. Chhokar and A. L. Tucker Angiogenesis: Basic Mechanisms and Clinical Applications Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 253 - 280. [Abstract] [PDF]

				T.-S. Li, K. Hamano, M. Nishida, M. Hayashi, H. Ito, A. Mikamo, and M. Matsuzaki CD117+ stem cells play a key role in therapeutic angiogenesis induced by bone marrow cell implantation Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H931 - H937. [Abstract] [Full Text] [PDF]

				M. Hedman, J. Hartikainen, M. Syvanne, J. Stjernvall, A. Hedman, A. Kivela, E. Vanninen, H. Mussalo, E. Kauppila, S. Simula, et al. Safety and Feasibility of Catheter-Based Local Intracoronary Vascular Endothelial Growth Factor Gene Transfer in the Prevention of Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic Myocardial Ischemia: Phase II Results of the Kuopio Angiogenesis Trial (KAT) Circulation, June 3, 2003; 107(21): 2677 - 2683. [Abstract] [Full Text] [PDF]

				S. Babaei, K. Teichert-Kuliszewska, Q. Zhang, N. Jones, D. J. Dumont, and D. J. Stewart Angiogenic Actions of Angiopoietin-1 Require Endothelium-Derived Nitric Oxide Am. J. Pathol., June 1, 2003; 162(6): 1927 - 1936. [Abstract] [Full Text] [PDF]

				F. W. Sellke Gene therapy in cardiac surgery: Is there a role? J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 994 - 997. [Full Text] [PDF]

				E. Imai Gene Therapy for Renal Diseases: Its Potential and Limitation J. Am. Soc. Nephrol., April 1, 2003; 14(4): 1102 - 1104. [Full Text] [PDF]

				T. D. Henry, B. H. Annex, G. R. McKendall, M. A. Azrin, J. J. Lopez, F. J. Giordano, P.K. Shah, J. T. Willerson, R. L. Benza, D. S. Berman, et al. The VIVA Trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis Circulation, March 18, 2003; 107(10): 1359 - 1365. [Abstract] [Full Text] [PDF]

				N. Tomita, R. Morishita, Y. Taniyama, H. Koike, M. Aoki, H. Shimizu, K. Matsumoto, T. Nakamura, Y. Kaneda, and T. Ogihara Angiogenic Property of Hepatocyte Growth Factor Is Dependent on Upregulation of Essential Transcription Factor for Angiogenesis, ets-1 Circulation, March 18, 2003; 107(10): 1411 - 1417. [Abstract] [Full Text] [PDF]

				E. R Mohler III, S. Rajagopalan, J. W Olin, J. D Trachtenberg, H. Rasmussen, R. Pak, and R. G Crystal Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial Vascular Medicine, February 1, 2003; 8(1): 9 - 13. [Abstract] [PDF]

				H Arakawa, U Ikeda, Y Hojo, S Ueno, M Nonaka-Sarukawa, K Yamamoto, and K Shimada Decreased serum vascular endothelial growth factor concentrations in patients with congestive heart failure Heart, February 1, 2003; 89(2): 207 - 208. [Full Text] [PDF]

				M. Rajasekaran, A. Kasyan, W. Allilain, and M. Monga Ex Vivo Expression of Angiogenic Growth Factors and Their Receptors in Human Penile Cavernosal Cells J Androl, January 1, 2003; 24(1): 85 - 90. [Abstract] [Full Text] [PDF]

				J.-S. Silvestre, N. Kamsu-Kom, M. Clergue, M. Duriez, and B. I. Levy Very-Low-Dose Combination of the Angiotensin-Converting Enzyme Inhibitor Perindopril and the Diuretic Indapamide Induces an Early and Sustained Increase in Neovascularization in Rat Ischemic Legs J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1038 - 1043. [Abstract] [Full Text] [PDF]

				M. Onimaru, Y. Yonemitsu, M. Tanii, K. Nakagawa, I. Masaki, S. Okano, H. Ishibashi, K. Shirasuna, M. Hasegawa, and K. Sueishi Fibroblast Growth Factor-2 Gene Transfer Can Stimulate Hepatocyte Growth Factor Expression Irrespective of Hypoxia-Mediated Downregulation in Ischemic Limbs Circ. Res., November 15, 2002; 91(10): 923 - 930. [Abstract] [Full Text] [PDF]

				M. R. Jaff Pharmacotherapy for Peripheral Arterial Disease: Emerging Therapeutic Options Angiology, November 1, 2002; 53(6): 627 - 633. [Abstract] [PDF]

				M. C. Cid, J. Hernandez-Rodriguez, M.-J. Esteban, M. Cebrian, Y. S. Gho, C. Font, A. Urbano-Marquez, J. M. Grau, and H. K. Kleinman Tissue and Serum Angiogenic Activity Is Associated With Low Prevalence of Ischemic Complications in Patients With Giant-Cell Arteritis Circulation, September 24, 2002; 106(13): 1664 - 1671. [Abstract] [Full Text] [PDF]

				V. Chekanov, R. Rayel, D. Krum, I. Alwan, J. Hare, T. Bajwa, and M. Akhtare Electrical Stimulation Promotes Angiogenesis in a Rabbit Hind-Limb Ischemia Model Vascular and Endovascular Surgery, September 1, 2002; 36(5): 357 - 366. [Abstract] [PDF]

				Y. Yang, J.-Y. Min, J. S. Rana, Q. Ke, J. Cai, Y. Chen, J. P. Morgan, and Y.-F. Xiao VEGF enhances functional improvement of postinfarcted hearts by transplantation of ESC-differentiated cells J Appl Physiol, September 1, 2002; 93(3): 1140 - 1151. [Abstract] [Full Text] [PDF]

				T.-S. Li, K. Hamano, K. Suzuki, H. Ito, N. Zempo, and M. Matsuzaki Improved angiogenic potency by implantation of ex vivo hypoxia prestimulated bone marrow cells in rats Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H468 - H473. [Abstract] [Full Text] [PDF]

				S. Pislaru, S. P. Janssens, B. J. Gersh, and R. D. Simari Defining Gene Transfer Before Expecting Gene Therapy: Putting the Horse Before the Cart Circulation, July 30, 2002; 106(5): 631 - 636. [Full Text] [PDF]

				A. Takahashi, Y. Kureishi, J. Yang, Z. Luo, K. Guo, D. Mukhopadhyay, Y. Ivashchenko, D. Branellec, and K. Walsh Myogenic Akt Signaling Regulates Blood Vessel Recruitment during Myofiber Growth Mol. Cell. Biol., July 1, 2002; 22(13): 4803 - 4814. [Abstract] [Full Text] [PDF]

				B. S. Zuckerbraun and E. Tzeng Vascular Gene Therapy: A Reality of the 21st Century Arch Surg, July 1, 2002; 137(7): 854 - 861. [Abstract] [Full Text] [PDF]

				I. Masaki, Y. Yonemitsu, A. Yamashita, S. Sata, M. Tanii, K. Komori, K. Nakagawa, X. Hou, Y. Nagai, M. Hasegawa, et al. Angiogenic Gene Therapy for Experimental Critical Limb Ischemia: Acceleration of Limb Loss by Overexpression of Vascular Endothelial Growth Factor 165 but not of Fibroblast Growth Factor-2 Circ. Res., May 17, 2002; 90(9): 966 - 973. [Abstract] [Full Text] [PDF]

				S.-i. Yoshimura, R. Morishita, K. Hayashi, J. Kokuzawa, M. Aoki, K. Matsumoto, T. Nakamura, T. Ogihara, N. Sakai, and Y. Kaneda Gene Transfer of Hepatocyte Growth Factor to Subarachnoid Space in Cerebral Hypoperfusion Model Hypertension, May 1, 2002; 39(5): 1028 - 1034. [Abstract] [Full Text] [PDF]

				K. Hamano, T.-S. Li, T. Kobayashi, K. Hirata, M. Yano, M. Kohno, and M. Matsuzaki Therapeutic angiogenesis induced by local autologous bone marrow cell implantation Ann. Thorac. Surg., April 1, 2002; 73(4): 1210 - 1215. [Abstract] [Full Text] [PDF]

				T. T. Rissanen, I. Vajanto, M. O. Hiltunen, J. Rutanen, M. I. Kettunen, M. Niemi, P. Leppanen, M. P. Turunen, J. E. Markkanen, K. Arve, et al. Expression of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 (KDR/Flk-1) in Ischemic Skeletal Muscle and Its Regeneration Am. J. Pathol., April 1, 2002; 160(4): 1393 - 1403. [Abstract] [Full Text] [PDF]

				M. C. Kim, A. Kini, and S. K. Sharma Refractory angina pectoris: Mechanism and therapeutic options J. Am. Coll. Cardiol., March 20, 2002; 39(6): 923 - 934. [Abstract] [Full Text] [PDF]

				M. Shimpo, U. Ikeda, Y. Maeda, M. Takahashi, H. Miyashita, H. Mizukami, M. Urabe, A. Kume, T. Takizawa, M. Shibuya, et al. AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model Cardiovasc Res, March 1, 2002; 53(4): 993 - 1001. [Abstract] [Full Text] [PDF]

				C. Emanueli, M. Bonaria Salis, T. Stacca, G. Pintus, R. Kirchmair, J. M. Isner, A. Pinna, L. Gaspa, D. Regoli, C. Cayla, et al. Targeting Kinin B1 Receptor for Therapeutic Neovascularization Circulation, January 22, 2002; 105(3): 360 - 366. [Abstract] [Full Text] [PDF]

				J.A. NAGY, E. VASILE, D. FENG, C. SUNDBERG, L.F. BROWN, E.J. MANSEAU, A.M. DVORAK, and H.F. DVORAK VEGF-A Induces Angiogenesis, Arteriogenesis, Lymphangiogenesis, and Vascular Malformations Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 227 - 238. [Abstract] [PDF]

				K.S. MOULTON Plaque Angiogenesis: Its Functions and Regulation Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 471 - 482. [Abstract] [PDF]

				R. SCHULZ, C. HUMMEL, S. HEINEMANN, W. SEEGER, and F. GRIMMINGER Serum Levels of Vascular Endothelial Growth Factor Are Elevated in Patients with Obstructive Sleep Apnea and Severe Nighttime Hypoxia Am. J. Respir. Crit. Care Med., January 1, 2002; 165(1): 67 - 70. [Abstract] [Full Text] [PDF]

				S. B. Freedman and J. M. Isner Therapeutic Angiogenesis for Coronary Artery Disease Ann Intern Med, January 1, 2002; 136(1): 54 - 71. [Abstract] [Full Text] [PDF]

				H. Huwer, C. Welter, C. Ozbek, M. Seifert, U. Straub, P. Greilach, G. Kalweit, and H. Isringhaus Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease Eur. J. Cardiothorac. Surg., December 1, 2001; 20(6): 1128 - 1134. [Abstract] [Full Text] [PDF]

				Y. Taniyama, R. Morishita, K. Hiraoka, M. Aoki, H. Nakagami, K. Yamasaki, K. Matsumoto, T. Nakamura, Y. Kaneda, and T. Ogihara Therapeutic Angiogenesis Induced by Human Hepatocyte Growth Factor Gene in Rat Diabetic Hind Limb Ischemia Model: Molecular Mechanisms of Delayed Angiogenesis in Diabetes Circulation, November 6, 2001; 104(19): 2344 - 2350. [Abstract] [Full Text] [PDF]

				M. Azrin Angiogenesis, protein and gene delivery Br. Med. Bull., October 1, 2001; 59(1): 211 - 225. [Abstract] [Full Text] [PDF]

				D. H. Weinberg, D. Simovic, J. Isner, and A. H. Ropper Chronic ischemic monomelic neuropathy from critical limb ischemia Neurology, September 25, 2001; 57(6): 1008 - 1012. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baumgartner, I. Articles by Isner, J. M. Search for Related Content PubMed PubMed Citation Articles by Baumgartner, I. Articles by Isner, J. M.